Login to Your Account

Biotie Therapies Walks Away From Newron Acquisition

By Cormac Sheridan
BioWorld International Correspondent

Wednesday, November 2, 2011

Biotie Therapies Oyj has closed the door on its proposed stock-based acquisition of Newron Pharmaceuticals SpA, following Merck Serono SA's surprise decision to exit a partnership with Newron on the Parkinson's drug safinamide.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription